Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Synapse. 2017 Oct 7;72(1):10.1002/syn.22012. doi: 10.1002/syn.22012

Figure 2. Acute cocaine-induced locomotion after GHSR1a antagonist treatment.

Figure 2

(A) Cocaine-induced locomotion was measured in C57BL/6J YIL781 treated WT mice (n=5–6 mice/group; ANOVA: interaction P < 0.0001; treatment P < 0.01). Tukey`s post hoc comparisons of different doses of YIL781 and vehicle revealed significant differences at multiple time points (*p<0.05). (B) Effect of pre-treatment with 10 and 20 mg/kg YIL781 on cocaine-mediated locomotion evaluated by total distanced moved over the 30 min post-cocaine injection period (ANOVA: treatment P < 0.0006) Tukey`s post hoc test: 10mg/kg YIL781 vs saline, *p< 0.05; 20mg/kg YIL781 vs saline, ***p < 0.001; 20mg/kg YIL781 vs 5 or 10 mg/kg YIL781, #p<0.05). (C) ANOVA analysis of 10 mg/kg YIL781 treatment on locomotor activity compared to vehicle (treatment P=0.66), interaction P=0.29).